Phase 3 Trial of Acalabrutinib in Combination with Venetoclax, With and Without Obinutuzumab Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

被引：0
|
作者：
Brown, Jennifer R. [1 ]
Eichhorst, Barbara [2 ]
Ghia, Paolo [3 ,4 ]
Kater, A. P. [5 ]
Li, Jianyong [6 ]
Khurana, Sudha [7 ]
Elhamy, Mostafa [7 ]
Wang, Min Hui [7 ]
Seymour, John F. [8 ,9 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Hosp Cologne, Cologne, Germany
[3] Univ Vita Salute Raffaele, Milan, Italy
[4] IRCCS Osped San Raffaele, Milan, Italy
[5] Amsterdam UMC, Amsterdam, Netherlands
[6] Nanjing Med Univ, Affiliated Hosp 1, Jiansu Sheng, Peoples R China
[7] Acerta Pharma, San Francisco, CA USA
[8] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[9] Royal Melbourne Hosp, Melbourne, Vic, Australia
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷
关键词：
CLL; chronic lymphocytic leukemia; acalabrutinib; Bruton tyrosine kinase inhibitor; combination therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-092
引用
收藏
页码：S221 / S222
页数：2
相关论文
共 50 条
  • [11] Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
    Byrd, John C.
    Hillmen, Peter
    Ghia, Paolo
    Kater, Arnon P.
    Chanan-Khan, Asher
    Furman, Richard R.
    O'Brien, Susan
    Yenerel, Mustafa Nuri
    Illes, Arpad
    Kay, Neil
    Garcia-Marco, Jose A.
    Mato, Anthony
    Pinilla-Ibarz, Javier
    Seymour, John F.
    Lepretre, Stephane
    Stilgenbauer, Stephan
    Robak, Tadeusz
    Rothbaum, Wayne
    Izumi, Raquel
    Hamdy, Ahmed
    Patel, Priti
    Higgins, Kara
    Sohoni, Sophia
    Jurczak, Wojciech
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (31) : 3441 - +
  • [12] Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia
    Sharman, Jeff P.
    Burke, John M.
    Yimer, Habte A.
    Boxer, Michael A.
    Babu, Sunil
    Li, Jia
    Mun, Yong
    Danilov, Alexey V.
    LEUKEMIA & LYMPHOMA, 2021, 62 (04) : 791 - 800
  • [13] Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective
    Owen, Carolyn J.
    Stewart, Douglas A.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2015, 6 (04) : 161 - 170
  • [14] Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States
    Cho, Sang Kyu
    Manzoor, Beenish S.
    Sail, Kavita R.
    Parise, Helene
    Ravelo, Arliene
    Shapouri, Sheila
    Kapustyan, Tatyana
    Sharmokh, Simon
    Virabhak, Suchin
    Davids, Matthew S.
    Johnson, Scott
    PHARMACOECONOMICS, 2020, 38 (09) : 941 - 951
  • [15] A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL)
    Chen, Christine I.
    Paul, Harminder
    Snitzler, Susi
    Kakar, Sumeet
    Le, Lisa W.
    Wei, Ellen N.
    Lau, Anthea
    Johnston, James B.
    Gibson, Spencer B.
    Queau, Michelle
    Spaner, David
    Croucher, Danielle
    Sherry, Barbara
    Trudel, Suzanne
    LEUKEMIA & LYMPHOMA, 2019, 60 (04) : 980 - 989
  • [16] Genomic Alterations and Outcomes With Fixed-Duration Ibrutinib plus Venetoclax: Results From the Phase 3 GLOW Study in Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
    Kater, Arnon
    Hodkinson, Brendan
    Moreno, Carol
    Munir, Talha
    Levin, Mark-David
    Niemann, Carsten
    Qi, Keqin
    Sinet, Pierre
    Baeten, Kurt
    Caces, Donne Bennett
    Srinivasan, Srimathi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S329 - S329
  • [17] Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
    Fischer, Kirsten
    Cramer, Paula
    Busch, Raymonde
    Boettcher, Sebastian
    Bahlo, Jasmin
    Schubert, Joeerg
    Pflueger, Karl H.
    Schott, Silke
    Goede, Valentin
    Isfort, Susanne
    von Tresckow, Julia
    Fink, Anna-Maria
    Buehler, Andreas
    Winkler, Dirk
    Kreuzer, Karl-Anton
    Staib, Peter
    Ritgen, Matthias
    Kneba, Michael
    Doehner, Hartmut
    Eichhorst, Barbara F.
    Hallek, Michael
    Stilgenbauer, Stephan
    Wendtner, Clemens-Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (26) : 3209 - 3216
  • [18] Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial
    Sharman, Jeff P.
    Egyed, Miklos
    Jurczak, Wojciech
    Skarbnik, Alan
    Pagel, John M.
    Flinn, Ian W.
    Kamdar, Manali
    Munir, Talha
    Walewska, Renata
    Corbett, Gillian
    Fogliatto, Laura Maria
    Herishanu, Yair
    Banerji, Versha
    Coutre, Steven
    Follows, George
    Walker, Patricia
    Karlsson, Karin
    Ghia, Paolo
    Janssens, Ann
    Cymbalista, Florence
    Woyach, Jennifer A.
    Salles, Gilles
    Wierda, William G.
    Izumi, Raquel
    Munugalavadla, Veerendra
    Patel, Priti
    Wang, Min Hui
    Wong, Sofia
    Byrd, John C.
    LANCET, 2020, 395 (10232) : 1278 - 1291
  • [19] BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed-Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)
    Wierda, William G.
    Pagel, John M.
    Davids, Mathew S.
    Zinzani, Pier Luigi
    Lu, Yi
    Liu, Hui
    Shahda, Safi
    Leow, Ching Ching
    Tam, Constantine S.
    Woyach, Jennifer
    Eyre, Toby A.
    Mato, Anthony R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S267 - S267
  • [20] Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease
    Al-Sawaf, O.
    Zhang, C.
    Tandon, M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 10 - 11
12345